Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT06747351 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06747351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06747351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Recruiting
Start date
May 6, 2025
Completion date
June 25, 2028
Enrollment
59 (estimated)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

chronic inflammatory demyelinating polyradiculoneuropathy (cidp)